TY - JOUR T1 - Telmisartan and ramipril were equivalent, but their combination increased adverse events in vascular disease or diabetes JF - Evidence Based Medicine JO - Evid Based Med SP - 147 LP - 147 DO - 10.1136/ebm.13.5.147 VL - 13 IS - 5 A2 - , Y1 - 2008/10/01 UR - http://ebm.bmj.com/content/13/5/147.abstract N2 - S YusufDr S Yusuf, Hamilton Health Sciences, Hamilton, Ontario, Canada; yusufs@mcmaster.caDesign:randomised controlled trial (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial [ONTARGET]).Allocation:concealed.*Blinding:blinded (patients, clinicians, and outcome assessors).*Setting:733 centres in 40 countries.Patients:25 620 patients ⩾55 years of age (mean age 66 y, 73% men) who had coronary or peripheral artery disease, cerebrovascular disease, or diabetes with end-organ damage. Exclusion criteria included intolerance to or inability to discontinue angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and congestive heart failure (HF).Intervention:telmisartan, 80 mg/day (n = 8542); ramipril, 5 mg/day in the first 2 weeks, … ER -